Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype

Cell Cycle

Volumn 11, Issue 10, 2012, Pages 1966-1976

  Ricci, Francesca ^a   Bernasconi, Sergio ^a   Perego, Patrizia ^b   Ganzinelli, Monica ^a   Russo, Giorgio ^a   Bono, Francesca ^b   Mangioni, Costantino ^b   Fruscio, Robert ^b   Signorelli, Mauro ^b   Broggini, Massimo ^a   Damia, Giovanna ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

Author keywords

Anticancer agents; Mesenchymal phenotype; Ovarian tumor; PKH26; Tumor initiating cell

Indexed keywords

5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; ETOPOSIDE; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CARCINOGENICITY; CELL DIFFERENTIATION; CELL ISOLATION; CELL POPULATION; CELL RENEWAL; CELL SORTER; CONTROLLED STUDY; CYTOTOXICITY; EPITHELIUM; EXCISION REPAIR; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MESENCHYMAL STEM CELL; MESENCHYME CELL; MOUSE; NONHUMAN; OVARY CARCINOMA; PHENOTYPE; STAINING;

EID: 84861378928     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.20308     Document Type: Article

References (40)

1. Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I. Management of borderline ovarian neoplasms. J Clin Oncol 2007; 25:2928-37; PMID:17617524; http://dx.doi.org/10.1200/JCO.2007.10.8076.
2. Boman BM, Wicha MS. Cancer stem cells: a step toward the cure. J Clin Oncol 2008; 26:2795-9; PMID:18539956; http://dx.doi.org/10.1200/ JCO.2008.17.7436.
3. Alison MR, Lim SM, Nicholson LJ. Cancer stem cells: problems for therapy? J Pathol 2011; 223:147- 61; PMID:21125672; http://dx.doi.org/10.1002/ path.2793.
4. Hermann PC, Bhaskar S, Cioffi M, Heeschen C. Cancer stem cells in solid tumors. Semin Cancer Biol 2010; 20:77-84; PMID:20371287; http://dx.doi. org/10.1016/j.semcancer.2010.03.004.
5. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009; 8:806-23; PMID:19794444; http://dx.doi.org/10.1038/nrd2137.
6. Tysnes BB. Tumor-initiating and -propagating cells: cells that we would like to identify and control. Neoplasia 2010; 12:506-15; PMID:20651980.
7. Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005; 65:3025-9; PMID:15833827.
8. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008; 68:4311-20; PMID:18519691; http://dx.doi.org/10.1158/0008-5472.CAN-08-0364.
9. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 2009; 8:158-66; PMID:19158483; http://dx.doi. org/10.4161/cc.8.1.7533.
10. Alvero AB, Fu HH, Holmberg J, Visintin I, Mor L, Marquina CC, et al. Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells 2009; 27:2405-13; PMID:19658191; http://dx.doi. org/10.1002/stem.191.
11. + cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010; 29:2672-80; PMID:20190812; http://dx.doi. org/10.1038/onc.2010. 35.
12. Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009; 27:2875-83; PMID:19816957.
13. Kusumbe AP, Mali AM, Bapat SA. CD133-expressing stem cells associated with ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature. Stem Cells 2009; 27:498-508; PMID:19253934; http://dx.doi.org/10.1634/stemcells.2008-0868.
14. Gatto C, Rieppi M, Borsotti P, Innocenti S, Ceruti R, Drudis T, et al. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin Cancer Res 1999; 5:3603-7; PMID:10589777.
15. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005; 65:5506-11; PMID:15994920; http://dx.doi.org/10.1158/0008-5472.CAN-05-0626.
16. Cicalese A, Bonizzi G, Pasi CE, Faretta M, Ronzoni S, Giulini B, et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 2009; 138:1083-95; PMID:19766563; http://dx.doi.org/10. 1016/j.cell.2009.06.048.
17. Kusumbe AP, Bapat SA. Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res 2009; 69:9245-53; PMID:19951996; http://dx.doi. org/10.1158/0008-5472.CAN-09-2802.
18. Carrassa L, Montelatici E, Lazzari L, Zangrossi S, Simone M, Broggini M, et al. Role of Chk1 in the differentiation program of hematopoietic stem cells. Cell Mol Life Sci 2010; 67:1713-22; PMID:20146081; http://dx.doi.org/10.1007/ s00018-010-0274-1.
19. 2 cell cycle phase that is associated with apoptotic resistance. BMC Cancer 2010; 10:166; PMID:20426848; http://dx.doi. org/10.1186/1471-2407-10-166.
20. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008; 8:545-54; PMID:18511937; http://dx.doi. org/10.1038/nrc2419.
21. Garvalov BK, Acker T. Cancer stem cells: a new framework for the design of tumor therapies. J Mol Med (Berl) 2011; 89:95-107; PMID:20890588; http:// dx.doi.org/10.1007/s00109-010-0685-3.
22. Schmidt P, Abken H. The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth. Oncotarget 2011; 2:313-20; PMID:21487158.
23. Di J, Duiveman-de Boer T, Figdor CG, Torensma R. Eradicating cancer cells: struggle with a chameleon. Oncotarget 2011; 2:99-101; PMID:21378413.
24. Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 2010; 101:293-9; PMID:19961486; http://dx.doi. org/10.1111/j.1349-7006.2009.01419.x.
25. Ahmed N, Abubaker K, Findlay J, Quinn M. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets 2010; 10:268-78; PMID:20370691; http://dx.doi. org/10.2174/156800910791190175.
26. Kemper K, Grandela C, Medema JP. Molecular identification and targeting of colorectal cancer stem cells. Oncotarget 2010; 1:387-95; PMID:21311095.
27. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100:3983-8; PMID:12629218; http://dx.doi. org/10.1073/pnas. 0530291100.
28. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15:504-14; PMID:18049477; http://dx.doi.org/10.1038/sj.cdd.4402283.
29. + cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 2009; 106:16281-6; PMID:19805294; http://dx.doi. org/10.1073/pnas.0905653106.
30. Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, Tsai TH, et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res 2008; 14:4085-95; PMID:18593985; http://dx.doi. org/10.1158/1078-0432.CCR-07-4404.
31. Kalluri R, Weinberg RA. The basics of epithelialmesenchymal transition. J Clin Invest 2009; 119:1420- 8; PMID:19487818; http://dx.doi.org/10.1172/ JCI39104.
32. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008; 14:818-29; PMID:18539112; http://dx.doi.org/10.1016/j.devcel.2008.05.009.
33. Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Menendez JA. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle 2010; 9:3807- 14; PMID:20890129; http://dx.doi.org/10. 4161/ cc.9.18.13131.
34. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Martin- Castillo B, Joven J, Menendez JA. Metformin against TGFβ-induced epithelial-to- mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle 2010; 9:4461-8; PMID:21088486; http://dx.doi.org/10.4161/ cc.9.22.14048.
35. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133:704-15; PMID:18485877; http://dx.doi. org/10.1016/j.cell.2008. 03.027.
36. Radisky DC, LaBarge MA. Epithelial-mesenchymal transition and the stem cell phenotype. Cell Stem Cell 2008; 2:511-2; PMID:18522839; http://dx.doi. org/10.1016/j.stem.2008.05.007.
37. Wong AS, Maines-Bandiera SL, Rosen B, Wheelock MJ, Johnson KR, Leung PC, et al. Constitutive and conditional cadherin expression in cultured human ovarian surface epithelium: influence of family history of ovarian cancer. Int J Cancer 1999; 81:180- 8; PMID:10188716; http://dx.doi.org/10.1002/ (SICI)1097-0215(19990412)81:2<180::AIDIJC3>3.0.CO;2-7.
38. Elliott A, Adams J, Al-Hajj M. The ABCs of cancer stem cell drug resistance. IDrugs 2010; 13:632-5; PMID:20799146.
39. Gossage L, Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 2007; 33:565-77; PMID:17707593; http://dx.doi.org/10.1016/j. ctrv.2007.07.001.
40. Walsh CS, Ogawa S, Karahashi H, Scoles DR, Pavelka JC, Tran H, et al. ERCC5 is a novel biomarker of ovarian cancer prognosis. J Clin Oncol 2008; 26:2952- 8; PMID:18565881; http://dx.doi.org/10.1200/ JCO.2007.13.5806.